Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. More Details
Mediocre balance sheet with limited growth.
Share Price & News
How has Tanvex BioPharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6541 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 6541's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 6541 underperformed the TW Biotechs industry which returned 21.7% over the past year.
Return vs Market: 6541 underperformed the TW Market which returned 28.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Tanvex BioPharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StAre Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?
1 month ago | Simply Wall StDoes Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?
5 months ago | Simply Wall StWe're Keeping An Eye On Tanvex BioPharma's (TPE:6541) Cash Burn Rate
Is Tanvex BioPharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6541's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6541's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6541 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 6541 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6541's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6541 is overvalued based on its PB Ratio (6.5x) compared to the TW Biotechs industry average (4.8x).
How is Tanvex BioPharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6541 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6541 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6541 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6541's revenue (143.4% per year) is forecast to grow faster than the TW market (11.1% per year).
High Growth Revenue: 6541's revenue (143.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6541 is forecast to be unprofitable in 3 years.
How has Tanvex BioPharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6541 is currently unprofitable.
Growing Profit Margin: 6541 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6541 is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.
Accelerating Growth: Unable to compare 6541's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6541 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 6541 has a negative Return on Equity (-152.84%), as it is currently unprofitable.
How is Tanvex BioPharma's financial position?
Financial Position Analysis
Short Term Liabilities: 6541's short term assets (NT$1.0B) exceed its short term liabilities (NT$308.3M).
Long Term Liabilities: 6541's short term assets (NT$1.0B) exceed its long term liabilities (NT$268.7M).
Debt to Equity History and Analysis
Debt Level: 6541's debt to equity ratio (6.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 6541's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6541 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 6541 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 18% each year
What is Tanvex BioPharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6541's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6541's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6541's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6541's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6541's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Allen Chao (74 yo)
Dr. Allen Chao, Ph.D., serves as Chief Executive Officer of Tanvex BioPharma, Inc. Dr. Chao served as Senior Advisor at Delos Advisors Limited. He is Founder of Tanvex Biologics, Inc. and serves as its Exe...
CEO Compensation Analysis
Compensation vs Market: Allen's total compensation ($USD716.45K) is above average for companies of similar size in the TW market ($USD196.23K).
Compensation vs Earnings: Allen's compensation has increased whilst the company is unprofitable.
|CEO & Director||no data||NT$20.06m||no data|
|Chief Scientific Officer & Director||5.67yrs||NT$2.61m||0.81% |
|Independent Director||5.67yrs||NT$682.00k||no data|
|Independent Director||5.67yrs||NT$617.00k||no data|
|Independent Director||5.67yrs||NT$697.00k||no data|
|Chairman of the Board||2.08yrs||NT$6.26m||no data|
Experienced Board: 6541's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.7%.
Tanvex BioPharma, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Tanvex BioPharma, Inc.
- Ticker: 6541
- Exchange: TSEC
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$10.922b
- Shares outstanding: 311.61m
- Website: https://www.tanvex.com
- Tanvex BioPharma, Inc.
- 802, West Bay Road
- Grand Pavilion
- George Town
- Grand Cayman
- Cayman Islands
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6541||TSEC (Taiwan Stock Exchange)||Yes||Ordinary Shares||TW||TWD||Aug 2015|
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Its products ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/21 08:39|
|End of Day Share Price||2021/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.